Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
16.23
+0.14 (0.87%)
At close: Mar 5, 2026, 4:00 PM EST
16.23
0.00 (0.00%)
Pre-market: Mar 6, 2026, 6:56 AM EST
Sarepta Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 2,198 | 1,902 | 1,243 | 933.01 | 701.89 | Upgrade
|
| Revenue Growth (YoY) | 15.58% | 52.97% | 33.26% | 32.93% | 29.95% | Upgrade
|
| Cost of Revenue | 2,362 | 1,124 | 1,028 | 1,017 | 862.13 | Upgrade
|
| Gross Profit | -163.43 | 778.36 | 215.61 | -84.07 | -160.24 | Upgrade
|
| Selling, General & Admin | 491.72 | 557.87 | 481.87 | 451.42 | 282.66 | Upgrade
|
| Amortization of Goodwill & Intangibles | 2.62 | 2.41 | 1.56 | 0.71 | 0.71 | Upgrade
|
| Operating Expenses | 494.34 | 560.28 | 483.43 | 452.14 | 283.37 | Upgrade
|
| Operating Income | -657.77 | 218.08 | -267.82 | -536.2 | -443.61 | Upgrade
|
| Interest Expense | -38.14 | -18.39 | -22.01 | -53.25 | -63.53 | Upgrade
|
| Interest & Investment Income | 30.76 | 30.64 | 36.26 | 16.49 | 0.35 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.94 | -0.06 | -0.91 | -6.92 | -0.94 | Upgrade
|
| EBT Excluding Unusual Items | -667.09 | 230.27 | -254.49 | -579.88 | -507.72 | Upgrade
|
| Merger & Restructuring Charges | -42.01 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -9.99 | 38.35 | 20.92 | 8.66 | -4.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 102 | - | 102 | Upgrade
|
| Other Unusual Items | 16.86 | -7.84 | -388.53 | -118.74 | -8.9 | Upgrade
|
| Pretax Income | -702.23 | 260.77 | -520.1 | -689.96 | -418.95 | Upgrade
|
| Income Tax Expense | 11.19 | 25.54 | 15.88 | 13.53 | -0.17 | Upgrade
|
| Net Income | -713.41 | 235.24 | -535.98 | -703.49 | -418.78 | Upgrade
|
| Net Income to Common | -713.41 | 235.24 | -535.98 | -703.49 | -418.78 | Upgrade
|
| Shares Outstanding (Basic) | 100 | 95 | 92 | 88 | 81 | Upgrade
|
| Shares Outstanding (Diluted) | 100 | 108 | 92 | 88 | 81 | Upgrade
|
| Shares Change (YoY) | -7.19% | 16.75% | 5.53% | 7.75% | 4.24% | Upgrade
|
| EPS (Basic) | -7.13 | 2.47 | -5.80 | -8.03 | -5.15 | Upgrade
|
| EPS (Diluted) | -7.13 | 2.34 | -5.80 | -8.03 | -5.15 | Upgrade
|
| Free Cash Flow | -307.45 | -342.74 | -577.1 | -356.17 | -481.66 | Upgrade
|
| Free Cash Flow Per Share | -3.07 | -3.18 | -6.25 | -4.07 | -5.93 | Upgrade
|
| Gross Margin | -7.43% | 40.92% | 17.34% | -9.01% | -22.83% | Upgrade
|
| Operating Margin | -29.92% | 11.47% | -21.54% | -57.47% | -63.20% | Upgrade
|
| Profit Margin | -32.45% | 12.37% | -43.11% | -75.40% | -59.66% | Upgrade
|
| Free Cash Flow Margin | -13.99% | -18.02% | -46.41% | -38.17% | -68.62% | Upgrade
|
| EBITDA | -613.25 | 255.81 | -223.43 | -494.34 | -405.59 | Upgrade
|
| EBITDA Margin | -27.90% | 13.45% | -17.97% | -52.98% | -57.79% | Upgrade
|
| D&A For EBITDA | 44.52 | 37.72 | 44.4 | 41.86 | 38.02 | Upgrade
|
| EBIT | -657.77 | 218.08 | -267.82 | -536.2 | -443.61 | Upgrade
|
| EBIT Margin | -29.92% | 11.47% | -21.54% | -57.47% | -63.20% | Upgrade
|
| Effective Tax Rate | - | 9.79% | - | - | - | Upgrade
|
| Revenue as Reported | 2,198 | 1,902 | 1,243 | 933.01 | 701.89 | Upgrade
|
| Advertising Expenses | 29.5 | 32 | 28.6 | 14.6 | 7.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.